Deep EigenMatics , Inc. filed for a patent titled MULTI-HEADED NEURAL NETWORKS FOR AI-BASED PROTEIN AND DRUG DESIGN with patent number US 12,725,677 B2 on September 1st, 2026.
Public source
Publisher name
Public post
I woke up to the news of another AI drug discovery patent, my 8th granted in the last twelve months, assigned to Deep EigenMatics, Inc. Delighted! What motivates me is t…
Company
Deep EigenMatics
Leading the Way to AI-Driven Breakthroughs in Drug Discovery
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2–10 employees
About Deep EigenMatics
Leading the Way to AI-Driven Breakthroughs in Drug Discovery
See moreDiscover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
NDA Group - an SSI Strategy Company
NDA Group - an SSI Strategy Company published draft guidelines from the European Commission clarifying how AI systems are classified as high-risk under the AI Act, including systems used in or constituting medical devices.
Legal & Regulatory
DrugPatentWatch Pharmaceutical Drug Patent Intelligence
DrugPatentWatch Pharmaceutical Drug Patent Intelligence reported that the new patent expiration for B Braun drug CLOROTEKAL is due in 2026.
Legal & Regulatory
Knowledge Valorisation and Academic Entrepreneurship - University of Padua, Italy
Knowledge Valorisation and Academic Entrepreneurship - University of Padua, Italy filed for a patent titled Innovative pre-filtering for Machine Learning and CNN for image analysis
Legal & Regulatory
Brown Bacon AI
Brown Bacon AI holds a patent pending application for AI Mee for Patient Care.
Legal & Regulatory
femtoAI